All In Biotech

Drug Trial Radar · NCT01278433

A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China

Large Scale Safety Study of IMOVAX Polio in Selected Cities in China, an Observational Post Marketing Study

Last checked: Nov 20, 2026Latest source record: Mar 29, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

5,007

Actual

Start

Dec 2010

Primary completion

Dec 2011

Study completion Jun 2012

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Jan 17, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 60 days, up to 89 days
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of the study is to collect post marketing safety data on IMOVAX Polio vaccine in China. Objective: To describe serious adverse events 30 days after each dose of IMOVAX Polio™ administered at 2, 3, and 4 months of age among infants living in the study cities of China.

Conditions

  • Polio
  • Poliomyelitis

Interventions

  • IMOVAX Polio™: Inactivated Poliomyelitis VaccineBiological

    0.5 mL, Intramuscular

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants reporting serious adverse events and relationship to Imovax Polio vaccination.Time frame: Up to 30 days after each vaccination

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Changsha, China

  • Site not named

    Chengdu, China

  • Site not named

    Chongqing, China

  • Site not named

    Hangzhou, China

  • Site not named

    Jinan, China

  • Site not named

    Kunming, China

  • Site not named

    Nanjing, China

  • Site not named

    Qingdao, China

  • Site not named

    Shenyang, China

  • Site not named

    Shenzhen, China

  • Site not named

    Tianjin, China

  • Site not named

    Wuhan, China

  • Site not named

    Xi'an, China

  • Site not named

    Zheng Zho, China

  • Site not named

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.